Journal Article
. 2005 Jun; 23(18):4179-91.
doi: 10.1200/JCO.2005.05.029.

Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide

Claudio Praga 1 Jonas Bergh  Judith Bliss  Jacques Bonneterre  Bruno Cesana  R Charles Coombes  Pierre Fargeot  Annika Folin  Pierre Fumoleau  Rosa Giuliani  Pierre Kerbrat  Michel Hery  Jonas Nilsson  Francesco Onida  Martine Piccart  Lois Shepherd  Patrick Therasse  Jacques Wils  David Rogers  
  • PMID: 15961765
  •     54 citations


Purpose: We reviewed follow-up of patients treated in 19 randomized trials of adjuvant epirubicin in early breast cancer to determine incidence, risk, and risk factors for subsequent acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Patients And Methods: The patients (N = 9,796) were observed from the start of adjuvant treatment (53,080 patient-years). Cases of AML or MDS (AML/MDS) were reported, with disease characteristics. Incidence and cumulative risk were compared for possible risk factors, for assigned regimens, and for administered cumulative doses of epirubicin and cyclophosphamide.

Results: In 7,110 patients treated with epirubicin-containing regimens (92% of whom also received cyclophosphamide), 8-year cumulative probability of AML/MDS was 0.55% (95% CI, 0.33% to 0.78%). The risk of developing AML/MDS increased in relation to planned epirubicin dose per cycle, planned epirubicin dose-intensity, and administered cumulative doses of epirubicin and cyclophosphamide. Patients with administered cumulative doses of both epirubicin and cyclophosphamide not exceeding those used in standard regimens (</= 720 mg/m(2) and </= 6,300 mg/m(2), respectively) had an 8-year cumulative probability of developing AML/MDS of 0.37% (95% CI, 0.13% to 0.61%) compared with 4.97% (95% CI, 2.06% to 7.87%) for patients administered higher cumulative doses of both epirubicin and cyclophosphamide.

Conclusion: Patients treated with standard cumulative doses of adjuvant epirubicin (</= 720 mg/m(2)) and cyclophosphamide (</= 6,300 mg/m(2)) for early breast cancer have a lower probability of secondary leukemia than patients treated with higher cumulative doses. Increased risk of secondary leukemia must be considered when assessing the potential benefit to risk ratio of higher than standard doses.

Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.
M Debled, N Houédé, +4 authors, Louis Mauriac.
Br J Cancer, 2007 Nov 15; 97(12). PMID: 18000502    Free PMC article.
Canadian supportive care recommendations for the management of neutropenia in patients with cancer.
C T Kouroukis, S Chia, +4 authors, J Mikhael.
Curr Oncol, 2008 Mar 05; 15(1). PMID: 18317581    Free PMC article.
Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases.
R Shivakumar, W Tan, +2 authors, M Wetzler.
Ann Oncol, 2008 May 10; 19(9). PMID: 18467310    Free PMC article.
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.
Lorenzo Gianni, Shari Gelber, +9 authors, Aron Goldhirsch.
Eur J Cancer, 2008 Dec 09; 45(4). PMID: 19062268    Free PMC article.
Breast cancer and the immune system.
Leanna J Standish, Erin S Sweet, +5 authors, Carolyn Torkelson.
J Soc Integr Oncol, 2009 Jan 13; 6(4). PMID: 19134448    Free PMC article.
Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer.
Sara López-Tarruella, Miguel Martín.
Breast Cancer Res, 2009 Apr 07; 11(2). PMID: 19344489    Free PMC article.
Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012).
Marilyn L Slovak, Victoria Bedell, +8 authors, Wendy Stock.
Breast Cancer Res Treat, 2009 Oct 24; 119(2). PMID: 19851858    Free PMC article.
Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.
Ashley N Mays, Neil Osheroff, +13 authors, David Grimwade.
Blood, 2009 Nov 04; 115(2). PMID: 19884644    Free PMC article.
Secondary malignancies across the age spectrum.
Andrea K Ng, Lisa B Kenney, Ethel S Gilbert, Lois B Travis.
Semin Radiat Oncol, 2009 Dec 05; 20(1). PMID: 19959033    Free PMC article.
T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report.
Manish Singhal, Vinod Raina, Ritu Gupta, Prasenjit Das.
Cases J, 2010 Jan 16; 3. PMID: 20076807    Free PMC article.
Molecular biology of therapy-related leukaemias.
Melanie Joannides, David Grimwade.
Clin Transl Oncol, 2010 Jan 19; 12(1). PMID: 20080465
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
Matti Aapro, Jeffrey Crawford, Didier Kamioner.
Support Care Cancer, 2010 Mar 02; 18(5). PMID: 20191292    Free PMC article.
Temozolomide-induced myelodysplasia.
Ethan A Natelson, David Pyatt.
Adv Hematol, 2010 Mar 13; 2010. PMID: 20224797    Free PMC article.
Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor.
Hyoeun Shim, Hyun-Sook Chi, +5 authors, Kyoo-Hyung Lee.
Korean J Hematol, 2010 Dec 02; 45(3). PMID: 21120206    Free PMC article.
Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
Henry G Kaplan, Judith A Malmgren, Mary K Atwood.
BMC Cancer, 2011 Jun 23; 11. PMID: 21693006    Free PMC article.
Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms.
Hilda Rachel Diamond, Maria Helena Ornellas, +11 authors, Eliana Abdelhay.
J Hematol Oncol, 2011 Sep 29; 4. PMID: 21951951    Free PMC article.
Molecular pathogenesis of secondary acute promyelocytic leukemia.
M Joannides, A N Mays, +8 authors, D Grimwade.
Mediterr J Hematol Infect Dis, 2011 Nov 24; 3(1). PMID: 22110895    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Can the risk of secondary cancer induction after breast conserving therapy be reduced using intraoperative radiotherapy (IORT) with low-energy x-rays?
Muhammad Hammad Aziz, Frank Schneider, +4 authors, Frederik Wenz.
Radiat Oncol, 2011 Dec 20; 6. PMID: 22176703    Free PMC article.
Incidence of acute myeloid leukemia after breast cancer.
Caterina Giovanna Valentini, Luana Fianchi, +3 authors, Livio Pagano.
Mediterr J Hematol Infect Dis, 2012 Jan 06; 3(1). PMID: 22220266    Free PMC article.
The co-presence of deletion 7q, 20q and inversion 16 in therapy-related acute myeloid leukemia developed secondary to treatment of breast cancer with cyclophosphamide, doxorubicin, and radiotherapy: a case report.
Ipek Yonal, Fehmi Hindilerden, +2 authors, Melih Aktan.
J Med Case Rep, 2012 Feb 22; 6. PMID: 22339850    Free PMC article.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents.
Ian G Cowell, Caroline A Austin.
Int J Environ Res Public Health, 2012 Jul 26; 9(6). PMID: 22829791    Free PMC article.
Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials.
H M Earl, L Hiller, +28 authors, NEAT Investigators and the SCTBG.
Br J Cancer, 2012 Oct 11; 107(8). PMID: 23047592    Free PMC article.
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008.
Lindsay M Morton, Graça M Dores, +5 authors, Rochelle E Curtis.
Blood, 2013 Feb 16; 121(15). PMID: 23412096    Free PMC article.
Squamous cell carcinomas of the tongue and oral cavity as secondary malignancies: what factors are implicated?
Franco Muggia.
Oncologist, 2013 Mar 15; 18(3). PMID: 23485623    Free PMC article.
Therapy-related acute promyelocytic leukemia: a systematic review.
Armin Rashidi, Stephen I Fisher.
Med Oncol, 2013 Jun 19; 30(3). PMID: 23771799
Systematic Review.
Chemotherapy causes cancer! A case report of therapy related acute myeloid leukaemia in early stage breast cancer.
J Cole Aidan, Nicole R Priddee, James J McAleer.
Ulster Med J, 2013 Oct 02; 82(2). PMID: 24082288    Free PMC article.
Second malignancies after breast cancer: The impact of adjuvant therapy.
Chunhui Dong, Ling Chen.
Mol Clin Oncol, 2014 Apr 29; 2(3). PMID: 24772296    Free PMC article.
Secondary Acute Lymphoblastic Leukemia after Hodgkin's Lymphoma or a Coincidental Association of Two Hematological Malignancies?
Mihaela Tevet, Cornel Dragan, +2 authors, Anca Roxana Lupu.
Maedica (Bucur), 2014 May 03; 8(4). PMID: 24790671    Free PMC article.
Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines.
Jennifer A Crozier, Abhisek Swaika, Alvaro Moreno-Aspitia.
World J Clin Oncol, 2014 Aug 13; 5(3). PMID: 25114866    Free PMC article.
Breast cancer survivorship: a comprehensive review of long-term medical issues and lifestyle recommendations.
Balazs I Bodai, Phillip Tuso.
Perm J, 2015 Apr 23; 19(2). PMID: 25902343    Free PMC article.
Current knowledge and future research directions in treatment-related second primary malignancies.
Lindsay M Morton, Anthony J Swerdlow, +4 authors, Flora E van Leeuwen.
EJC Suppl, 2015 Jul 29; 12(1). PMID: 26217162    Free PMC article.
Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
Gregory S Calip, Judith A Malmgren, +2 authors, Henry G Kaplan.
Breast Cancer Res Treat, 2015 Oct 10; 154(1). PMID: 26450505    Free PMC article.
Long-term Toxicity of Cancer Treatment in Older Patients.
Armin Shahrokni, Abraham J Wu, Jeanne Carter, Stuart M Lichtman.
Clin Geriatr Med, 2015 Nov 29; 32(1). PMID: 26614861    Free PMC article.
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Eileen E Parkes, Richard D Kennedy.
Oncologist, 2016 Mar 30; 21(5). PMID: 27022037    Free PMC article.
Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.
Anita Sveen, Inger Marie Løes, +10 authors, Ragnhild A Lothe.
PLoS Genet, 2016 Jul 30; 12(7). PMID: 27472274    Free PMC article.
Utility of Dexrazoxane for the Attenuation of Epirubicin-Induced Genetic Alterations in Mouse Germ Cells.
Sabry M Attia, Sheikh F Ahmad, +4 authors, Saleh A Bakheet.
PLoS One, 2016 Oct 01; 11(9). PMID: 27690233    Free PMC article.
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
Rachel A Freedman, D K Seisler, +17 authors, H B Muss.
Breast Cancer Res Treat, 2016 Nov 21; 161(2). PMID: 27866278    Free PMC article.
Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy.
Robbie G Majzner, Huzefa Mogri, +11 authors, Heather J Symons.
Biol Blood Marrow Transplant, 2017 Jan 08; 23(4). PMID: 28062216    Free PMC article.
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.
Alexios Matikas, Sara Margolin, +12 authors, Jonas Bergh.
Breast Cancer Res Treat, 2017 Dec 01; 168(2). PMID: 29190004    Free PMC article.
Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
Sakshi Jasra, Jesus Anampa.
Curr Treat Options Oncol, 2018 May 13; 19(6). PMID: 29752560
Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?
Ami N Shah, William J Gradishar.
Oncologist, 2018 Aug 19; 23(10). PMID: 30120159    Free PMC article.
Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France.
Marie Joelle Jabagi, Norbert Vey, +3 authors, Rosemary Dray-Spira.
JAMA Netw Open, 2019 Jan 19; 2(1). PMID: 30657534    Free PMC article.
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Bhausaheb Bagal, Rohit Kumar, +9 authors, Syed K Hasan.
Med Oncol, 2020 Apr 12; 37(5). PMID: 32277283
Chromatin regulators mediate anthracycline sensitivity in breast cancer.
Jose A Seoane, Jacob G Kirkland, +2 authors, Christina Curtis.
Nat Med, 2019 Nov 09; 25(11). PMID: 31700186    Free PMC article.
[Clinical analysis of 8 cases therapy related leukemia].
Wei Zhao, Hongmei Jing, +3 authors, Xiaoyan Ke.
Zhonghua Xue Ye Xue Za Zhi, 2015 Jun 03; 36(5). PMID: 26031536    Free PMC article.
[Clinical characteristics and prognosis of 35 patients with therapy-related hematological neoplasms].
Q S Lu, N Xu, +7 authors, X L Liu.
Zhonghua Xue Ye Xue Za Zhi, 2016 Apr 02; 37(3). PMID: 27033760    Free PMC article.
Adjuvant chemotherapy for node negative, high Recurrence ScoreTM breast cancer: in defense of de-escalation.
Diana Lake, Andrew D Seidman.
NPJ Breast Cancer, 2019 Aug 21; 5. PMID: 31428677    Free PMC article.
Prognostic Markers of Myelodysplastic Syndromes.
Yuliya Andreevna Veryaskina, Sergei Evgenievich Titov, +2 authors, Igor Fyodorovich Zhimulev.
Medicina (Kaunas), 2020 Jul 31; 56(8). PMID: 32727068    Free PMC article.
Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer.
Xenia Elena Bacinschi, Anca Zgura, Inga Safta, Rodica Anghel.
Cancer Manag Res, 2020 Nov 28; 12. PMID: 33244272    Free PMC article.
Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non-Hodgkin lymphoma.
Stephen K Gruschkus, David Lairson, +2 authors, Xianglin L Du.
Cancer, 2010 Jul 29; 116(22). PMID: 20665502    Free PMC article.
A diffuse large B cell lymphoma emerging with breast cancer relapse.
Abdulkadir Karismaz, Mehmet Hilmi Dogu, +3 authors, Elif Suyani.
Pan Afr Med J, 2019 May 01; 31. PMID: 31037185    Free PMC article.
A Fibrinogen Alpha Fragment Mitigates Chemotherapy-Induced MLL Rearrangements.
Julia Eberle, Rahel Stefanie Wiehe, +7 authors, Lisa Wiesmüller.
Front Oncol, 2021 Jul 06; 11. PMID: 34222016    Free PMC article.